Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | SORD | Q00796 | 5/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.48 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28860184 | 0.83 | SORD (0.50) | SORDTRPV1OGA | |
| SCHEMBL2190955 | 0.81 | HRH4 (0.65) | HRH3SORDTRPV1HRH4 | |
| SCHEMBL29997962 | 0.81 | HRH4 (0.65) | HRH3SORDTRPV1HRH4 | |
| SCHEMBL20361177 | 0.81 | SORD (0.55) | SORDTRPV1 | |
| SCHEMBL15260059 | 0.81 | MAP4K4 (0.53) | HRH3SORDTRPV1OGAHRH4 | |
| SCHEMBL27901036 | 0.81 | HRH3 (0.69) | HRH3SORDOGAHRH4 | |
| SCHEMBL3960913 | 0.80 | HRH3 (0.65) | HRH3SORD | |
| SCHEMBL29519276 | 0.79 | TRPV1 (0.51) | HRH3SORDTRPV1OGAHRH4 | |
| SCHEMBL1427479 | 0.79 | TRPV1 (0.51) | HRH3SORDTRPV1OGAHRH4 | |
| SCHEMBL3949154 | 0.79 | TRPV1 (0.51) | HRH3SORDTRPV1OGAHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | disclosed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2013138860-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | STS, PGLS, PEPD | HRH3 3179/4885SORD 371/4885TRPV1 1392/4885 |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | STS, PEPD, PGLS | HRH3 3441/4885SORD 567/4885TRPV1 2311/4885 |
| US-20130252938-A1 | Antibacterial Compounds | STS, PGLS, PEPD | HRH3 3179/4885SORD 371/4885TRPV1 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.